EGFR and cancer: No consistent associations between TAP1 or TAP2 downregulation and age, gender, disease stage or smoking status were identified, and the frequency of cancer cell TAP1 and/or TAP2 downregulation was comparable across lung adenocarcinomas harboring activating mutations in EGFR or KRAS (Tables 1–2).